Stocks With Stable Returns? Noodles & Co (NDLS) and Antares Pharma Inc (ATRS)

Posted by admin May 7, 2015 0 Comment 525 views

New York, NY – GDP INSIDER  –  05/07/2014.

This article discusses two companies: Noodles & Co (NASDAQ:NDLS) and Antares Pharma Inc (NASDAQ:ATRS)

Noodles & Co (NASDAQ:NDLS) shares tumbled in trading yesterday by 19.4% to $16.70 per share.  The stock hit a new 52-week low and could see ongoing downward pressure.  It has broken through any level of support and may continue to selloff over the next trading week.  The decline in the shares was caused by another disappointing earnings report.  The company has missed on three of the last four quarters and could continue to underperform.  The company also made a big cut to guidance for 2015 after just one quarter.  It now expects flat EPS versus prior guidance of 20% growth.  A cut that significant to guidance so quickly after it was issued, and the quarterly misses should have investors questioning the quality of the management team.  From the outside, it looks as if management does not know their own business and cannot follow sector trends.

We Expect A Further Decline, Click Here To See How Much Noodles & Co Can Fall In Our Free NDLS Investment Report.    

Antares Pharma Inc (NASDAQ:ATRS) stock fell by 7% on Wednesday to $2.14 after it issued the pricing of its follow on offering to raise additional capital.  Antares Pharma will issue another 20 million shares of common stock at $2.00 per share raising $37.6 million for the company.  The underwriters have 30 days to purchase up to another 3 million shares of the Ewing, New Jersey based company.   The specialty pharmaceutical company has a current market cap of $275 million and a 52-week trading range of $1.82 – $3.20.  It develops and commercializes parenteral pharmaceutical and technologies worldwide.  In its next earnings update, investors should look for new details on its Quickshot Testosterone (QS-T) product that could help the shares.  Last quarter, the company was able to sign multiple managed care contracts to help get Otrexup prescriptions increased.  The drug was also listed as the preferred drug in some pharmacy benefit plans over its competitor.  More news around treatment development and distribution could drive the shares higher.

Is Antares Pharma Inc Moving In A Right Direction? Click Here To See Our Target Price For ATRS.

About Ultimate Stock Alerts covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit

Disclosure: is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Write Your Comment